Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Urinary Bladder Neoplasms

Neoplasm Metastasis

Breast Neoplasms, Patient Compliance

Breast Neoplasms

Pancreatic Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Brain Neoplasms, Breast Neoplasms

Head and Neck Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Osteitis Deformans

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

HER2 Positive Breast Cancer

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Pituitary Neoplasms, Prolactinoma

Colorectal Neoplasms

HER2-Positive Early Stage Breast Cancer

Brain Neoplasms, Breast Neoplasms, Neoplasms

Melanoma, Skin Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Ductal, Breast

Endometrial Neoplasms

Carcinoma, Ovarian Epithelial

Breast Neoplasms, Diarrhea, Neoplasms

Breast Neoplasms

Brain Neoplasms, Ependymoma, Spinal Cord Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Gliosarcoma

Gallbladder Neoplasms

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

MOST plus

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

HELEX

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

TRYHARD

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

ROME

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

GW

TEAL

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

MetAction

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

HERACLES

PAMELA

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

TCHL Phase II

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

GW572016 to Treat Recurrent Malignant Brain Tumors

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen